These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34994049)

  • 1. Impact of de novo donor-specific HLA antibodies on pediatric kidney transplant prognosis in patients with acute declined or stable allograft function.
    Fylaktou A; Karava V; Vittoraki A; Zampetoglou A; Papachristou M; Antoniadis N; Iniotaki A; Mitsioni A; Printza N
    Pediatr Transplant; 2022 May; 26(3):e14221. PubMed ID: 34994049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d⁺ Antibody-Mediated Rejection in Kidney Transplant Recipients.
    Tatapudi VS; Kopchaliiska D; da Gente GJ; Buenaventura OF; Singh M; Laszik Z; Adey DB; Rajalingam R
    Ann Transplant; 2021 Dec; 26():e934175. PubMed ID: 34848674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk.
    Baghai Arassi M; Gauche L; Schmidt J; Höcker B; Rieger S; Süsal C; Tönshoff B; Fichtner A
    Pediatr Nephrol; 2022 Oct; 37(10):2503-2514. PubMed ID: 35166920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunction.
    Dieplinger G; Everly MJ; Rebellato LM; Haisch CE; Briley KP; Bolin P; Kendrick WT; Kendrick SA; Morgan C; Harland RC; Terasaki PI
    Transplantation; 2014 Nov; 98(10):1097-104. PubMed ID: 24911039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of
    López Del Moral C; Wu K; Naik M; Osmanodja B; Akifova A; Lachmann N; Stauch D; Hergovits S; Choi M; Bachmann F; Halleck F; Schrezenmeier E; Schmidt D; Budde K
    Front Med (Lausanne); 2022; 9():943502. PubMed ID: 36186822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study.
    Bertrand D; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Galinier A; Laurent C; Etienne I; Farce F; François A; Guerrot D
    Transplantation; 2020 Aug; 104(8):1726-1737. PubMed ID: 32732853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.
    Lachmann N; Niemann M; Reinke P; Budde K; Schmidt D; Halleck F; Pruß A; Schönemann C; Spierings E; Staeck O
    Am J Transplant; 2017 Dec; 17(12):3076-3086. PubMed ID: 28613392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study.
    Schinstock CA; Dadhania DM; Everly MJ; Smith B; Gandhi M; Farkash E; Sharma VK; Samaniego-Picota M; Stegall MD
    Transpl Int; 2019 May; 32(5):502-515. PubMed ID: 30597643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of de novo donor-specific anti-HLA antibodies in kidney graft failure: A case-control study.
    Castro A; Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    HLA; 2017 Nov; 90(5):267-275. PubMed ID: 28776960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective De Novo Donor-Specific Antibody Monitoring in Renal Transplant Patients.
    Fylaktou A; Sampani E; Kasimatis E; Nikolaidou V; Dimitriadis C; Anastasiou A; Papachristou M; Chatzika G; Papagianni A
    Transplant Proc; 2021 Nov; 53(9):2765-2768. PubMed ID: 34598809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
    Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
    Moayedi Y; Fan CS; Tinckam KJ; Ross HJ; McCaughan JA
    Clin Transplant; 2018 Nov; 32(11):e13416. PubMed ID: 30276870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.
    Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J
    Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant de novo non donor-specific HLA antibodies are not associated with poor graft outcome in non-sensitized pediatric recipients of kidney transplantation.
    Cioni M; Comoli P; Tagliamacco A; Innocente A; Basso S; Fontana I; Magnasco A; Trivelli A; Nocco A; Macchiagodena M; Catenacci L; Klersy C; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Nocera A
    Transpl Immunol; 2021 Apr; 65():101375. PubMed ID: 33610675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Anti-HLA De Novo Donor Specific Antibody on Graft Outcomes in Pancreas Transplantation: A Meta-Analysis.
    Khan SM; Sumbal R; Schenk AD
    Transplant Proc; 2021 Dec; 53(10):3022-3029. PubMed ID: 34772490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
    Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
    Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
    Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.